explore -WSS

explore

author：fashion 2025-09-06 02:04:28 - browse：2498

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why Charlie Gard's case is so disturbing to Americans

focus

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

A preacher's new calling: Diversifying neuroscience research

A preacher's new calling: Diversifying neuroscience research

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Why Charlie Gard's case is so disturbing to Americans

Phenylephrine and the overlooked value of the placebo effect

explore

explore

leisure time

Hollywood unions extend contract negotiations for actors

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Continuity nursing helped my family in our darkest PICU moments

Allen Institute goes after foundational questions, CEO Costa says

At least 13 dead in Texas as scorching temps continue

Stories you might have missed in 2023: health, science, medicine

As demand for Covid shots wanes, Moderna seeks its next success

STAT Virtual Event: JPM Recap, Live!

Medical leaders decry Supreme Court decision on affirmative action

Allen Institute goes after foundational questions, CEO Costa says

focus

VC firm General Catalyst wants to buy a health system

3 questions for the future of Biden's cancer moonshot

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

FDA rejects Alnylam's heart disease treatment over insufficient data

Gene therapy denied for Afghan refugee whose father aided U.S.

focus

Wikipedia

leisure time

hotspot